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A

sthma is a chronic inflammatory disease that affects
300 million people worldwide. Its prevalence ranges
from 1% to 18% of the population in different countries.1
The World Health Organization has estimated that 15
million disability-adjusted life years are lost annually due
to asthma. Worldwide deaths from asthma are estimated
at 250 000 per year. Furthermore, asthma is a major cause
of absence from work in many countries, including United
States.2
The prevalence of asthma has increased over the last ten
years around the world. One of the suggested explanations
to this increment is the western lifestyle hypothesis in
countries that are going through a transition from a more
traditional to a more modern lifestyle, as has been described
in China.3 The prevalence of asthma in China is 2.1%,4
which results in an addition of 20 million asthmatics.
Prevalence varies from region to region in China, for
example, in Jinan it is reported as 1.1%, which is less than
most western countries; however, asthma control is below
the goals established by the Global Initiative for Asthma.5
The case fatality in China reported by GINA is 36.7/100
000.
The management of patients with asthma can be
challenging since patient population is diverse when it
comes to phenotypes and endotypes.6,7 Furthermore, the
overlapping of asthma with other obstructive pulmonary
diseases makes it difficult for targeted therapy. The
cornerstone in the management includes the use of inhaled
corticosteroids, to keep asthma under clinical control.
Although, different populations, like Chinese, might have a
better response to one steroid compared to another.8 Other
commonly used medications include anti-leukotrienes,
anti-immunoglobulin E and methylxanthines. Further
therapies have been tried to target different steps in the
inflammatory cascade seen in asthma.9,10 Recently, studies
in the management of airway smooth muscle (ASM) have
demonstrated that this can be an excellent target to control
asthma. Bronchial thermoplasty is one of the most recent
therapies that targets airway smooth muscle.
AIRWAY SMOOTH MUSCLE
There has been major progress in the field of ASM biology
over the last few years. ASM has been identified to play a
significant role in the pathogenesis of obstructive airways
diseases. 11 Further research is underway evaluating

immunomodulation and airway remodeling of ASM.12
Alterations in the excitation-contraction coupling within the
myocytes of ASM has been demonstrated in patients with
asthma compared to normal subjects.13 This may promote
airway hyperresponsiveness in asthma and other obstructive
diseases. Furthermore, in vitro studies have shown that
ASM secrete chemokines such as CXCL10 and fractalkine,
as well as cytokines that are important in the autocrine
loop, perpetuating airway inflammation and angiogenesis,
that contribute to an already complex immunomodulatory
role.14 Multiple studies have identified an increase in the
ASM mass in patients with asthma. This occurred by
either hypertrophy and/or hyperplasia of myocytes.15,16
These changes also contribute to hyperresponsiveness and
bronchoconstriction of airways.
BRONCHIAL THERMOPLASTY
Bronchial thermoplasty (BT) is a new approach for the
management of severe asthma that specifically targets
ASM to reduce its mass in order to control airway
hyperresponsiveness; effect that is seen even by high
resolution computed tomography.17 This is accomplished
by bronchoscopic delivered radiofrequency ablation to
the airway walls.18 The actin-myosin interaction chain is
disrupted by the high temperatures generated by the high
frequency alternating current. Through denaturation of
the motor proteins, disruption of the ASM spasm cascade
is accomplished.19,20 In previous studies, BT has already
shown to have long term effects with the reduction of ASM
mass in healthy dogs and humans.21,22
Other contributing mechanisms of bronchial thermoplasty
include modification of the extracellular matrix (leading
to fixation of the airway structure) and reduction in
mucous gland hyperplasia.23 BT also leads to ablation of
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“pacemakers” found in large and medium-size airways. The
additive effects of decreased hyperreactivity is reflected in
the reduction of downstream modulatory effect in small
and medium-size airways, which have been hypothesized
to contribute in the pathophysiology of asthma.24,25
BRONCHIAL THERMOPLASTY: TECHNIQUE
BT is performed via fiberoptic bronchoscopy, with the
patient under moderate sedation in an outpatient setting. It
requires three separate bronchoscopic procedures (at two to
three weeks intervals), in which all the visualized airways
distal to the mainstem bronchi (down to three mm) are
treated, with the exception of the right middle lobe. The
first two sessions are dedicated to treat each lower lobe
separately, and the third session targets both upper lobes.
The thermal energy utilized in BT is delivered via the
Alair system (Boston Scientific, Natick, MA, USA), which
consists of a radiofrequency (RF) electrical generator
(controller) and a single-use, long, flexible catheter with
an expandable electrode array attached at one end and a
deployment handle at the other (Figures 1 and 2). The
electrode array expands to contact the airway walls and
then activated to deliver RF energy for ten seconds each
time (Figure 3). If improper contact occurs between the
array and the airway walls the system signals the operator.
As AF energy is oscillatory electrical current, the patient
is connected to the Alair controller through an electrode to
create a closed circuit. A flexible bronchoscope with a 2.0
mm working channel is required for the procedure. As in
any airway procedure with the transfer of energy, oxygen
supplementation to the patient should be reduced to less
than 40% fraction of inspired oxygen to minimize the risk
of ignition during activation. The number of activations
required per procedure varies due to anatomical differences
in patients as well as operator experience with 40 to 110
activations occurring per lobe.

electronic device, hypersensitivity to the drugs used during
the bronchoscopy, and severe comorbidities that increase
the risk of adverse events (Table 1). The previous studies
performed with BT did not include patients who had three
or more hospitalizations for asthma, three or more lower
respiratory tract infections, and four or more episodes of
oral corticosteroids use for asthma exacerbations in the
previous year.26-28 Patients undergoing BT should be treated
with a 5-day course of prednisone (50 mg/d), beginning two
days before the procedure. This has been found to decrease
the airway inflammation caused by BT and the subsequent
minor post procedure morbidities.
BRONCHIAL THERMOPLASTY: SAFETY AND
EFFICACY
After multiple studies in canines with the use of BT
demonstrating reduction in the airway responsiveness
to local methacholine provocation, 21,29 and persistent
histologic reduction in the ASM mass,21 the first feasibility
study in human airways was performed by Miller et al22 in
eight non-asthmatic patients who underwent lobectomy for
lung cancer. This study showed a reduction in 50% of the
ASM mass of the treated airways, with no adverse effects.
Cox et al 30 found a significant reduction in airway
hyperresponsiveness (for up to two years) in sixteen
patients with mild to moderate asthma who underwent BT.
Adverse events included airway inflammation that required
a temporary increase in asthma medications.

Since these studies, three randomized, controlled trials
have been performed with the use of BT: the Asthma
Intervention Research (AIR) study, Research in Severe
Asthma (RISA) study, and the AIR2 trial.26-28 The AIR
trial26 randomized 112 patients with moderate to severe
asthma to BT and control. At twelve months, there were
significant improvements in the morning peak expiratory
flow, scores on the Asthma Quality of Life Questionnaire
Contraindications to BT include presence of an implantable
(AQLQ), and Asthma Control Questionnaire (ACQ) in
the BT group compared to
control. However, there was
no significant difference in
airway responsiveness and
forced expiratory volume in 1
second (FEV 1) between both
groups. Adverse effects were
more common in the BT group
during the first six weeks after
the treatment, which included
Figure 1. Asthmatx AF Controller (Alair System).
dyspnea, wheezing, cough, and
Figure 2. Bronchial thermoplasty catheter with electrodes in open position.
night awakenings; however,
Figure 3. Alair catheter opened in airway with electrodes approximating the airway wall.
Table 1. Indications and contraindications of bronchial thermoplasty
Indications
Adults with severe persistent asthma41 defined by:
Daily symptoms
Nightime symptoms more than 7 days per week
Use of short-acting beta 2-agonists several times per day to relieve symptoms
FEV1 <60% predicted; FEV1/FVC reduced >5%

Contraindications
Presence of implanted electronic device
Hypersensitivity to the drugs used during bronchoscopy
Severe medical conditions that will increase the risk of adverse events during bronchoscopy
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there was no significant difference in the treatment and
control groups during the period of six weeks and twelve m
onths post treatment.
In 2007, the RISA trial27 enrolled 32 patients with refractory
severe asthma who were on high doses of inhaled steroids
and oral prednisone. The BT group again demonstrated
a significant reduction in the use of rescue medication
as well as improvement in AQLQ and ACQ compared
to control up to 1 year. It was also possible to reduce the
dose of oral steroids in the bronchial thermoplasty group,
although this was not statistically significant. The bronchial
thermoplasty treated group had post-procedure morbidities,
which included seven hospitalizations due to worsening
asthma (four patients) and lobar collapse (two patients) that
required bronchoscopy for suctioning of secretions. In order
to minimize the subjective effect over the improvement
of the AQLQ (primary outcome in the AIR2), the AIR2
trial was performed.28 This was a randomized, doubleblind, sham-controlled study of 288 subjects with severe
persistent asthma (defined by the Severe Asthma Working
Group31) on high-dose of inhaled corticosteroids. However,
patients with FEV1 post-bronchodilator of less than 65%
were excluded, as well as patients with four or more asthma
exacerbations requiring systemic steroids, or three or more
upper respiratory infections in the previous year. Excluding
these criteria changes the definition of severe asthma.
The AIR2 trial did show a significant difference in
improvement of AQLQ in the BT group compared to the
sham group. There was also a significant improvement
of AQLQ in the sham group, which was unexpected and
persisted during the initial twelve months of follow-up.
The treated group had a significant reduction in severe
exacerbations (32% reduction vs. sham), unscheduled office
visits (23% reduction vs. sham), emergency department
visits (84% reduction vs. sham), hospitalizations (73%
reduction vs. sham), as well as a statistical reduction in
days missed from work or school in the BT group for
the fifty-two weeks follow-up post-treatment. Short-term
adverse effects related to BT in this study included airway
inflammation and upper respiratory infections, which were
similar to previous BT studies.
There are several studies providing data regarding longterm effects of BT. Thomson et al32 found an absence of
clinical complications (respiratory events, hospitalizations
and emergency department visits) over a period of five
years post BT in forty-five patients treated in the AIR trial.
Despite the improved clinical condition of patients, there
was no change in the lung capacity over the same period
of time. Castro et al33 followed the BT-group patients from
the AIR2 trial for two years and found the same rate of
respiratory events compared to the first year post treatment,
however no comparison with patients with the shamgroup occurred. The AIR2 study’s five years follow-up is
currently closing worldwide, with long-term data hopefully
available in 2014.
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The United States Federal Drug Administration (FDA)
approved the use of BT in 2010 for the treatment of severe
persistent asthma in patients 18 years and older (Table 1),
with different centers already reporting their favorable
experiences,34,35 as well as developing histological grading
systems36 that can be used in the future. However, the
routine use of this therapy has not been spreading as
quickly as it is still recognized by most medical insurance
companies in the United States as experimental and is
therefore not paid for. Besides, further questions will need
to be answered before this technique continues to spread
worldwide,37 like the long-term effects and the specific
population that BT can have a significant impact on,38,39
knowing that failure can also happen.40
CONCLUSIONS
Given the high prevalence of asthma worldwide, as well
as its social and economical impact, further investigations
regarding new therapies for asthma are needed. BT is a
novel therapy that targets ASM in an attempt to reduce its
mass and decrease hyperresponsiveness of the airways.
BT consists of applying radiofrequency ablation, through
flexible bronchoscopy, to the ASM. Multiple blinded
controlled randomized studies have demonstrated the
effectiveness and safety of bronchial thermoplasty. BT is
a complex bronchoscopic procedure. To maximize safety
and effectiveness, the procedure should be performed at
centers with experience in complex airways procedures.
Further studies assessing long-term effects of BT and in
which subgroups therapy will have the most impact are still
pending or needed.
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